

## AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 10, line 15 with the following rewritten paragraph:

Figure ~~9~~12 shows FACS plots demonstrating that GCS pretreatment of monocytes (GM) increases PHA stimulated T lymphocyte apoptosis ( $T+GM = 45\%$ ) compared to monocytes (M) not treated with GCS ( $T+M = 31\%$ ), 1-methyl-tryptophan (M-TRP) reduced T lymphocyte apoptosis in control cultures ( $T+M+M-TRP = 23\%$ ) and in GCS-treated monocyte + T cells ( $T+GM+M-TRP = 32\%$ ). (Note T = T lymphocytes; M = monocytes; GM = GCS-pretreated monocytes).

Please replace the paragraph beginning at page 10, line 22 with the following rewritten paragraph:

Figure ~~10~~13 shows FACS plots demonstrating that GCS pretreatment of monocytes (GM) increases recall antigen mixture (consisting of influenza A virus, tetanus toxoid and candida) stimulated T lymphocyte apoptosis ( $T+GM = 51\%$ ) compared to monocytes (M) not treated with GCS ( $T+M = 13\%$ ). The inhibitor 1-methyl-tryptophan (M-TRP) reduced T lymphocyte apoptosis in control cultures ( $T+M+M-TRP = 18\%$ ) and in GCS-treated monocyte + T cells ( $T+GM+M-TRP = 40\%$ ).

Please replace the paragraph beginning at page 15, line 25 through page 16, line 2 with the following rewritten paragraph:

GCS for use in the present invention can be prepared from any known glioblastoma cell line, although variation in the immunosuppressive strength of the resulting preparation is expected. (See Table I). A nonlimiting list of suitable cell lines include SNB 19 (DSMZ no. ACC 325), U251, ~~ATCC accession numbers CRL-1620~~, T98G (ATCC no. CRL-1690), DBTRG-05MG (ATCC no. CRL-2020), M059K (ATCC no. CRL 2365), M059J (ATCC no. CRL-2366), ~~HTB-14~~, U118 MG (ATCC no. HTB-15), ~~HTB-16~~, ~~HTB-17~~, A172 (ATCC no. CRL-1620), A1207, A1235, A2781, U87 MG (ATCC no. HTB-14), U138 MG (ATCC no. HTB-16), and U373 MG (ECACC no. 89081403).